AstraZeneca's BAXdrostat Meets Primary Endpoint in Phase III Trial

TL;DR

AZN's BAXdrostat trial successful for resistant hypertension, potential new drug incoming.

AI Summary

AstraZeneca PLC announced on July 14, 2025, that its investigational medicine BAXdrostat met the primary endpoint in the BAXHTN Phase III trial. The trial evaluated BAXdrostat as a potential treatment for resistant hypertension.

Why It Matters

This positive Phase III result for BAXdrostat could lead to a new treatment option for patients with resistant hypertension, a condition with significant unmet medical needs.

Risk Assessment

Risk Level: low — This filing is an informational report (6-K) announcing a clinical trial result, which is standard disclosure and does not inherently introduce new financial or operational risks.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• BAXdrostat (drug) — Investigational medicine
• BAXHTN (trial) — Phase III trial name
• July 14, 2025 (date) — Announcement date

FAQ

From the Filing

0001654954-25-008010.txt : 20250714 0001654954-25-008010.hdr.sgml : 20250714 20250714103050 ACCESSION NUMBER: 0001654954-25-008010 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250714 FILED AS OF DATE: 20250714 DATE AS OF CHANGE: 20250714 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251120417 BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a9003q.htm BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL a9003q FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of July 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __                               No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________           AstraZeneca PLC   INDEX TO EXHIBITS   1. Baxdrostat met primary endpt in BaxHTN PhIII trial   This announcement contains inside information   14 July 2025   Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension   Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo    Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favourable safety profile.   There are 1.3 billion people worldwide living with hypertension. 1  When uncontrolled, hypertension can lead to a higher risk of heart attack, stroke, heart failure and kidney disease. 2,3  In the US, approximately 50% of hypertensive patients who are on multiple treatments do not have their blood pressure under control. 4  Growing evidence points to aldosterone dysregulation as one of the key biological drivers of hypertension. 5,6   Dr. Bryan Williams, Chair of Medicine at University College London, pri